JE Cairnes School of Business and Economics, National University of Ireland Galway, Galway, Ireland.
Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK.
Thorax. 2015 Apr;70(4):376-8. doi: 10.1136/thoraxjnl-2013-204114. Epub 2014 Jun 10.
Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were £2912 (SD £2212) to £4217 (SD £2449). Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.
严重难治性哮喘在医疗成本方面带来了巨大负担，但对于导致这些成本的因素知之甚少。本研究利用英国胸科学会难治性哮喘注册中心（n=596）的数据，从国家卫生服务的角度估算直接医疗成本，并探讨了解释成本差异的因素。严重难治性哮喘患者的年平均治疗费用为 2912 英镑（SD=2212）至 4217 英镑（SD=2449）。成本的显著预测因子为 FEV1%预计值、治疗地点、维持口服皮质类固醇治疗和体重指数。治疗严重难治性哮喘患者给医疗服务带来了巨大的成本。
